Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL, Vitte J, Dombi E, Nguyen T, Wagle N, Ishiyama A, Sepahdari AR, Cachia D, Widemann BC, Brackmann DE, Doherty JK, Kalamarides M, Giovannini M. Nghiemphu PL, et al. Among authors: giovannini m. J Neurooncol. 2024 Apr;167(2):339-348. doi: 10.1007/s11060-024-04596-4. Epub 2024 Feb 19. J Neurooncol. 2024. PMID: 38372904 Free PMC article. Clinical Trial.
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M. Giovannini M, et al. Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10. Neuro Oncol. 2014. PMID: 24414536 Free PMC article.
Meningioma mouse models.
Kalamarides M, Peyre M, Giovannini M. Kalamarides M, et al. Among authors: giovannini m. J Neurooncol. 2010 Sep;99(3):325-31. doi: 10.1007/s11060-010-0331-5. Epub 2010 Aug 24. J Neurooncol. 2010. PMID: 20734219 Review.
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
Jordan JT, Orr CC, Thalheimer RD, Cambillo JV, Beauchamp RL, Shaikh G, Muzikansky A, Stemmer-Rachamimov A, Giovannini M, Kalamarides M, Barker FG 2nd, Ramesh V, Plotkin SR. Jordan JT, et al. Among authors: giovannini m. Neurooncol Adv. 2023 Apr 17;5(1):vdad041. doi: 10.1093/noajnl/vdad041. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37215956 Free PMC article.
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Fuse MA, et al. Among authors: giovannini m. Neuro Oncol. 2019 Mar 18;21(4):486-497. doi: 10.1093/neuonc/noz002. Neuro Oncol. 2019. PMID: 30615146 Free PMC article.
1,460 results